“A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients” (2014) European Journal of Oncology and Environmental Health, 18(4), pp. 173–180. Available at: https://mattioli1885journals.com/index.php/EJOEH/article/view/2443 (Accessed: 18 July 2024).